Insightfully repurposing established drugs for treating eye disorders - that’s our focus.
To provide relief for the millions of people globally that suffer from eye surface disorders by providing accessible and effective treatment solutions.
What We Do
Ocular Discovery develops disorder-specific formulations and delivery technologies to optimize the utility of the well-established heart medication, Dipyridamole*, for the treatment of eye surface disorders such as Dry Eye Disease, Conjunctivitis, Pterygium, Pinguecula, Melanocytic Nevus, and Corneal Neovascularization.
Approved in Israel for relief of symptoms of Dry Eye Disease, Pterygium & Pinguecula
Eye Diseases In Our Focus
Our pipeline targets eye diseases that affect 2 out of every 3 people worldwide over their lifetime.
Introduced in 1965, Dipyridamole was originally established as a treatment for cardiovascular disorders. The drug’s effectiveness foreshadowed its substantial promise for the treatment of retinal disorders of the eye and was further investigated for the application of ocular surface disease in 2012.
In 2017, Ocular Discovery tackled the challenging feat of creating the first temperature stable, soluble, topical Dipyridamole formulation to help millions of people suffering from painful and lifestyle disrupting eye surface disorders such as Dry Eye Disease, Conjunctivitis, Pterygium, Pinguecula, Melanocytic Nevus, and Corneal Neovascularization.
Dipyridamole is known to possess the following properties:
Dipyridamole and Eye Disorder Publications
Pterygium: nonsurgical treatment using topical dipyridamole - a case report
Topical Dipyridamole for Treatment of Pterygium and Associated Dry Eye Symptoms: Analysis of User-Reported Outcomes
Ocular Applications of Dipyridamole: A Review of Indications and Routes of Administration
Our Management Team
Sign up to receive email alerts with the latest news from Ocular Discovery